Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Cash from Financing Activities (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Cash from Financing Activities for 10 consecutive years, with $178.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities changed N/A to $178.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $324.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $323.0 million for FY2025, 5983301.26% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $178.9 million at Crescent Biopharma, up from $145.4 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $178.9 million in Q4 2025, with the low at $999.0 in Q4 2023.
  • Average Cash from Financing Activities over 4 years is $36.4 million, with a median of $600617.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities skyrocketed 7258.46% in 2021, then crashed 99.98% in 2024.
  • Over 4 years, Cash from Financing Activities stood at $1.1 million in 2021, then crashed by 99.91% to $999.0 in 2023, then surged by 390.29% to $4898.0 in 2024, then skyrocketed by 3651594.57% to $178.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $178.9 million, $145.4 million, and $4898.0 for Q4 2025, Q2 2025, and Q1 2024 respectively.